Core Insights - The Allstate Corporation reported estimated catastrophe losses of $175 million for January 2026, translating to $138 million after-tax, primarily due to Winter Storm Fern [1] Group 1: Catastrophe Losses - Estimated catastrophe losses for January 2026 were $175 million, with an after-tax impact of $138 million [1] - The losses were primarily related to Winter Storm Fern [1] Group 2: Protection Policies - As of January 31, 2026, Allstate had 25,484 thousand auto policies, a slight decrease of 0.1% from December 31, 2025, but an increase of 2.6% from January 31, 2025 [1] - Homeowners policies in force were 7,709 thousand, reflecting a 0.2% increase from December 31, 2025, and a 2.5% increase from January 31, 2025 [1] - Other personal lines showed a minor decrease of 0.1% from December 31, 2025, with 4,894 thousand policies, and a slight increase of 0.6% from January 31, 2025 [1] - Commercial lines decreased by 0.6% from December 31, 2025, totaling 175 thousand policies, and saw a significant decline of 14.2% from January 31, 2025 [1] - The total number of policies in force as of January 31, 2026, was 38,262 thousand, representing a 2.2% increase from December 31, 2025 [1]

Core Viewpoint - Curaleaf Holdings, Inc. has successfully closed a private placement of $500 million in senior secured notes, which will support its global growth initiatives and enhance capital flexibility in the cannabis sector [1]. Group 1: Financial Details - The private placement consists of $500 million aggregate principal amount of 11.5% senior secured notes due February 18, 2029 [1]. - The company will use the net proceeds to support global growth initiatives and pay transaction fees and expenses [1]. - The notes were issued at 100% of face value and are senior secured obligations, payable semi-annually until maturity [1]. Group 2: Strategic Implications - The successful closing of this private placement is seen as a strong endorsement of Curaleaf's long-term strategy and vision [1]. - The company aims to accelerate its global expansion and capture strategic opportunities in the international cannabis market [1]. - The issuance marks a pivotal moment for the cannabis sector, indicating renewed institutional demand and confidence in long-term growth [1]. Group 3: Regulatory and Market Context - The notes were offered on a private placement basis in Canada and the United States, adhering to applicable securities laws [1]. - Seaport Global Securities, LLC acted as the lead placement agent, with ATB Cormark Capital Markets as the co-placement agent [1]. - The notes are subject to a customary four-month hold period under Canadian securities laws [1].

Core Viewpoint - Vision Marine Technologies Inc. has filed a new U.S. patent application to support the development of its high-voltage electric marine powertrain platform, which includes a modular mechanical integration system for pairing electric motors with conventional outboard lower units [1] Company Developments - The patent application is aimed at enhancing the integration of electric motors in marine environments, addressing alignment tolerances and operational loads [1] - Vision Marine has recently acquired Nautical Ventures, a Florida-based dealership group, which will support its retail network [1]

Core Insights - Safehold Inc. has been named a finalist for the 2026 Ivory Prize for Housing Affordability, recognizing its innovative contributions to the affordable housing market [1] - The company aims to address the unmet demand for affordable housing, particularly in the context of rising interest rates and construction costs [1] - Safehold established a dedicated Affordable Housing team in 2025 to expand its investments in this sector [1] Company Overview - Safehold Inc. is a leader in the modern ground lease industry, having created it in 2017 [1] - The company focuses on helping owners of various property types, including multifamily and affordable housing, to generate higher returns with reduced risk [1] - Safehold operates as a real estate investment trust (REIT), aiming to provide safe, growing income and long-term capital appreciation to its shareholders [1] Industry Context - The Ivory Prize highlights the need for innovative and scalable solutions to tackle the U.S. housing affordability crisis [1] - The housing industry is described as fragmented and risk-averse, necessitating recognition of effective solutions to high costs [1] - The award aims to elevate successful strategies that can be replicated across the industry [1]

ATI Announces Multi-Year $500 Million Share Repurchase Program [Accessibility Statement] Skip NavigationDALLAS, Feb. 19, 2026 /PRNewswire/ -- ATI Inc. (NYSE: ATI) announced that its Board of Directors has authorized the additional repurchase of up to $500 million of its outstanding common stock, which the Company currently expects will support a multi-year share repurchase program in combination with the currently remaining $120 million from its prior authorization. Repurchases under the program may be made ...

Core Viewpoint - Thesis Gold Inc. has announced a strategic investment from AngloGold Ashanti, which will acquire 5% of the company's common shares for C$38.67 million, validating the potential of the Lawyers-Ranch Project [1] Group 1: Investment Details - AngloGold Ashanti will purchase 13,858,883 common shares at a price of C$2.79 per share, representing the volume weighted average price on February 18, 2026 [1] - Centerra Gold Inc. will also participate in the private placement, acquiring 2,059,730 common shares at the same price, resulting in a 9.9% ownership stake in the company [1] - The total gross proceeds from both subscriptions will amount to approximately C$44.41 million [1] Group 2: Use of Proceeds - Proceeds from the subscriptions will be allocated for working capital and general corporate purposes, including ongoing technical studies at the Lawyers-Ranch gold-silver Project [1] Group 3: Project Overview - The Lawyers-Ranch Project has demonstrated strong project economics, with a 54.4% after-tax internal rate of return (IRR) and an after-tax net present value (NPV) of C$2.37 billion at gold and silver prices of US$2,900/oz and US$35/oz, respectively [1] - The company is advancing the Environmental Assessment Process and plans to initiate a Feasibility Study in 2026 to further de-risk the project [1]

Core Insights - Insmed reported total revenues of $606.4 million for the full year 2025, with significant contributions from its products BRINSUPRI and ARIKAYCE [1][2] - The company anticipates full-year 2026 revenues for BRINSUPRI to be at least $1 billion and for ARIKAYCE to be between $450 million and $470 million [1][2] - Insmed's net loss for the fourth quarter of 2025 was $328.5 million, compared to a net loss of $235.5 million in the same quarter of 2024 [2][3] Financial Performance - Total revenues for the fourth quarter of 2025 were $263.8 million, a 153% increase compared to $104.4 million in the fourth quarter of 2024 [2] - ARIKAYCE revenues for the fourth quarter of 2025 were $119.2 million, reflecting a 14% growth year-over-year, while full-year revenues reached $433.8 million, a 19% increase from 2024 [2] - BRINSUPRI generated $144.6 million in the fourth quarter and $172.7 million for the full year 2025, marking its successful U.S. commercial launch [1][2] Research and Development Updates - Insmed is advancing its clinical programs, including the Phase 3 ENCORE trial for ARIKAYCE and additional Phase 3 studies for TPIP in patients with pulmonary conditions [1][2] - The company plans to submit a supplementary new drug application for ARIKAYCE in the second half of 2026, pending positive topline data from the ENCORE trial [1][2] - Insmed is also developing INS1148 and INS1201, targeting various respiratory and genetic diseases, with IND filings expected in 2026 [1][2] Cash Position and Future Guidance - As of December 31, 2025, Insmed had approximately $1.4 billion in cash, cash equivalents, and marketable securities, positioning the company for continued investment in its pipeline [1][2] - The company expects to maintain a focus on commercialization and expansion of its product offerings, particularly BRINSUPRI and ARIKAYCE, throughout 2026 [1][2] - Insmed anticipates that pre-clinical research programs will comprise less than 20% of overall expenditures, indicating a strategic focus on advancing clinical development [2]

Core Insights - Bandwidth Inc. reported strong financial results for Q4 and full year 2025, highlighting record Adjusted EBITDA and free cash flow, with a positive outlook for 2026, projecting approximately 16% revenue growth and 29% Adjusted EBITDA growth [1][2][3] Financial Performance - Q4 2025 revenue was $208 million, slightly down from $210 million in Q4 2024, while full year revenue increased to $754 million from $748 million in 2024 [1][3] - Gross margin for Q4 2025 was 38%, up from 36% in Q4 2024, and for the full year, it was 39%, compared to 37% in 2024 [1][3] - Non-GAAP net income for Q4 2025 was $11 million, down from $12 million in Q4 2024, while full year non-GAAP net income rose to $46 million from $41 million [1][3] - Adjusted EBITDA for Q4 2025 was $25 million, up from $23 million in Q4 2024, and for the full year, it increased to $93 million from $82 million [1][3] Cash Flow and Share Repurchase - Net cash provided by operating activities for Q4 2025 was $39 million, compared to $37 million in Q4 2024, while free cash flow was $31 million, slightly up from $30 million [1][3] - The Board of Directors authorized an $80 million share repurchase program, reflecting confidence in the company's growth strategy and cash flow generation [1][2] Customer Highlights - Bandwidth secured significant contracts with various enterprises, including a top-five global automaker and a major U.S. bank, showcasing the demand for its AI-driven communication solutions [1][2] - The company emphasized the increasing reliance on its Maestro platform and Communications Cloud for AI integration in production environments [1][2] 2026 Financial Outlook - For Q1 2026, Bandwidth expects revenue between $200 million and $203 million, and for the full year, revenue guidance is set between $864 million and $884 million [1][3] - Adjusted EBITDA guidance for Q1 2026 is projected between $21 million and $24 million, with full year guidance between $117 million and $123 million [1][3]

Core Insights - Compugen Ltd. is a clinical-stage cancer immunotherapy company that utilizes AI/ML for drug target discovery [1] - The company will participate in two upcoming investor conferences, including the Oppenheimer 36th Annual Healthcare Life Sciences Conference and the Leerink Partners 2026 Global Healthcare Conference [1] Company Overview - Compugen is focused on developing cancer immunotherapies through its AI/ML powered computational discovery platform, Unigen™ [1] - The company has two main programs targeting TIGIT: COM902, a fully owned anti-TIGIT antibody in Phase 1, and rilvegostomig, an Fc-reduced PD-1/TIGIT bispecific antibody in Phase 3 development by AstraZeneca [1] - Additional programs include COM701, a potential first-in-class anti-PVRIG antibody, and GS-0321, a high affinity anti-IL-18 binding protein antibody licensed to Gilead [1] Upcoming Events - The Oppenheimer conference will take place on February 26, 2026, featuring a fireside chat at 2 PM ET [1] - The Leerink Partners conference is scheduled for March 9, 2026, with a fireside chat at 8:40 AM ET [1] - Live webcasts of the fireside chats will be available on Compugen's Investor Relations website [1]

services are designed to be accurate, timely, and transparent. Our proactive approach and unique system of analysis and reconciliation ensure we do everything possible to maximize your recovery.About BroadridgeBroadridge Financial Solutions (NYSE: BR) is a global technology leader with trusted expertise and transformative technology, helping clients and the financial services industry operate, innovate, and grow. We power investing, governance, and communications for our clients – driving operational resili ...